

# CONTINUE TO ORDER ASTEPRO 0.15%



**Original ASTEPRO**  
NDC No. 0037-0242-30



**ASTEPRO 0.15%**  
NDC No. 0037-0243-30

**Original ASTEPRO is no longer available for reordering after January 15, 2010—ASTEPRO 0.15% is and will continue to be available**

- Do not return original ASTEPRO—sell your remaining original ASTEPRO and continue to reorder ASTEPRO 0.15%
- ASTEPRO 0.15% has no AB-rated generic equivalent—DO NOT SUBSTITUTE

**Please see Important Safety Information on reverse side.**

**Astepro® 0.15%**  
(azelastine HCl) Nasal Spray,  
205.5 mcg



# CONTINUE TO ORDER ASTEPRO 0.15%

## Greater concentration of azelastine HCl, with a great concentration of benefits

- First and only nasal antihistamine indicated for both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis
- First and only nasal antihistamine with once-daily dosing for SAR
- 50% greater concentration of azelastine HCl than original ASTEPRO (205.5 mcg vs 137 mcg per spray)
- Relieves rhinitis symptoms, including nasal congestion, without an added decongestant



Eligible patients will pay a maximum \$15 copay with their ASTEPRO 0.15% Savings Card\*



### Indication for ASTEPRO 0.15%

- ASTEPRO (azelastine HCl) Nasal Spray 0.15% is indicated for the relief of the symptoms of seasonal and perennial allergic rhinitis in patients 12 years of age and older

### Important Safety Information

- Avoid engaging in hazardous occupations requiring complete mental alertness when taking ASTEPRO Nasal Spray 0.15%
- Avoid concurrent use of alcohol or other central nervous system depressants with ASTEPRO Nasal Spray 0.15%
- In clinical studies, the most commonly reported adverse reactions, when dosed at 2 sprays per nostril once or twice daily, respectively, included bitter taste (4%, 6%), nasal discomfort (4%, 3%), epistaxis (2%, 1%), and sneezing (1%, 2%)

### Indication for original ASTEPRO

- ASTEPRO (azelastine HCl) Nasal Spray is indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older

### Important Safety Information

- The most commonly reported adverse events were dose related (1 and 2 sprays per nostril respectively) and included bitter taste (6%-7%), epistaxis (2%-3%), headache (1%-3%), nasal discomfort (0%-1%), fatigue (0%-2%), and somnolence (1%-2%)
- Avoid engaging in hazardous occupations requiring complete mental alertness when taking ASTEPRO Nasal Spray
- Avoid concurrent use of alcohol or other central nervous system depressants with ASTEPRO Nasal Spray

\*For eligible, insured patients only. Coupon covers the balance of the copay over \$15 (if any) for the first unit dispensed and for refills. Maximum value of \$100 per dispensed unit. Offer expires 12/31/2010. See Astepro.com for full program terms and conditions.

Please see accompanying full Prescribing Information.

**MEDA**  
PHARMACEUTICALS  
Meda Pharmaceuticals Inc.  
Somerset, New Jersey 08873-4120

© 2010 Meda Pharmaceuticals Inc.

AES9193

January 2010

**Astepro**<sup>®</sup> **0.15%**  
(azelastine HCl) Nasal Spray,  
205.5 mcg

